Synnovation Therapeutics Inc. has described heterocyclic compounds acting as nuclear factor erythroid 2-related factor 2 (NFE2-related factor 2; NFE2L2; NRF2) inhibitors reported to be useful for the treatment of cancer.

Onco3r Therapeutics BV has divulged fibroblast growth factor receptor 3 (FGFR3) inhibitors reported to be useful for the treatment of cancer.

Shandong Luye Pharmaceutical Co. Ltd. has identified salts of CDK2/cyclin E1 inhibitors reported to be useful for the treatment of cancer.

Lanova Medicines Ltd. has synthesized antibody-drug conjugates (ADCs) comprising antibodies targeting sialyl-Tn antigen (STn) linked to an exatecan derivative through a linker reported to be useful for the treatment of cancer.

Wigen Biomedicine Technology (Shanghai) Co. Ltd. has disclosed phosphatidylinositol 3-kinase α (PI3Kα) inhibitors reported to be useful for the treatment of solid cancers and hematological cancers.

Genescience Pharmaceuticals Co. Ltd. has described salts of known melanocortin MC4 receptor antagonists reported to be useful for the treatment of anorexia nervosa, cachexia, muscle atrophy, nausea and vomiting, sarcopenia, anxiety, bone disorders and inflammatory disorders.

Qingdao Putaike Biomedical Technology Co. Ltd. has divulged hydrophobic tag-based degraders comprising heat shock protein 90 (HSP90) ligands covalently linked to an androgen receptor (AR)-targeting moiety through a linker acting as AR degradation inducers reported to be useful for the treatment of acne, androgenic alopecia, hirsutism, metabolic disorders, breast cancer and prostate cancer.

China Pharmaceutical University and Chongqing Innovation Institute, China Pharmaceutical University have identified compounds acting as stimulator of interferon genes protein (STING; TMEM173) antagonists reported to be useful for the treatment of cancer, fibrosis, infections, inflammation, autoimmune diseases, metabolic disorders, neurological disorders and cardiovascular disorders, among others.

Zhejiang Yangli Pharmaceutical Technology Co. Ltd. has synthesized thiazole-substituted pyrimidine amine compounds acting as CDK2/cyclin E1 inhibitors reported to be useful for the treatment of cancer.

Université de Montréal has disclosed GTPase KRAS G12D mutant inhibitors reported to be useful for the treatment of cancer, inflammatory disorders and immunological disorders.